| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Medical Profiles & Engineering is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Danaher is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.
The Brain Tumor Society is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
USMD is a publicly held (NASDAQ: USMD), physician-led integrated healthcare system committed to exemplary patient care. Headquartered in Irving, Texas, USMD serves the Dallas-Fort Worth metropolitan area with more than 250 physicians and associate practitioners, and provides healthcare services to patients in just under 20 different specialties at its hospitals, nine cancer treatment centers and nearly 70 physician clinics. For more information about USMD, visit www.usmd.com.